Mannheim

• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended recruitment
  2024-514945-12-00 10 2018-09-03 locally advanced resectable adenocarcinoma of the oesophagogastric jun
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• Obinutuzumab in marginal zone lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (OLYMP-1) Ended recruitment
  2024-517476-38-00 4 2018-05-14 Marginal Zone Lymphoma
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple … Ended recruitment
  2023-504951-29-00 5 2017-07-27 Chron's Disease
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA … Ended recruitment
  2024-515619-23-00 4 2015-06-29 essential thrombocythemia
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit … Ended recruitment
  2024-512243-23-00 5 2014-11-07 gastrointestinal stromal tumor
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and … Halted
  2022-502903-31-00 5 2025-11-05 Patients with ADHD (according to ICD-10 / DSM-5)
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404 … Halted
  2023-505096-68-00 4 2025-01-14 Preclinical Alzheimer’s Disease
• Enhancing recovery in early schizophrenia: A study comparing cannabidiol and placebo as add-on to standard antipsychotic treatment. Halted
  2024-517198-26-00 4 2017-02-17 Remitted early phase schizophrenia
• "A study in healthy people to test how 2 different formulations of a combination treatment (vicadrostat and empagliflozin) are taken up in … Ended
  2025-521650-42-00 3 2025-09-04 Healthy volunteer trial
• A study in healthy men to test whether carbamazepine influences the amount of nerandomilast in the blood Ended
  2025-521279-30-00 3 2025-08-06 Healthy volunteer trial
• Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma Ended
  2024-510972-19-00 4 2025-03-13 Primary mediastinal large B-cell lymphoma (PMBCL)
• Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M … Ended
  2024-512562-34-00 4 2025-02-24 Type 2 Diabetes Mellitus
• An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination wi … Ended
  2024-512670-10-00 9 2025-02-13 Unresectable or Metastatic Melanoma
• With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia Ended
  2024-518971-76-00 4 2024-12-21 chronic myeloid leukemia in chronic phase
• Effects of AZD5004 in adults who are living with obesity or overweight with at least 1 weight-related medical condition Ended
  2024-513691-18-00 4 2024-12-11 Participants living with Obesity or Overweight with at least 1 comorbi
• Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended
  2024-517340-61-00 5 2024-11-19 Patients after curative intent resection of cholangiocarcinoma (intrah
• CK-0045 proof-of-concept study Ended
  2024-514191-41-00 4 2024-09-16 Type 2 diabetes and Obesity

Showing 265–288 of 361 trials